Form 4 Filing for Renton Hollings

Renton Hollings, a director at AnaptysBio, Inc., executed a Rule 10b5-1 trading plan on March 30, 2026. On October 1, 2026, Hollings acquired 5,000 shares of common stock at $18.03 per share, increasing their post-transaction holdings to 15,995 shares. Subsequently, Hollings disposed of 5,000 shares at a weighted average price of $49.8743 (ranging from $49.435 to $50.37), leaving them with 10,995 shares. Additionally, a vested stock option for 5,000 shares with an exercise price of $18.03 was exercised, resulting in 10,000 shares held post-transaction. Hollings also holds additional unvested options for up to 92,320 shares. The filing was signed by Christopher Murphy as Attorney-in-Fact on October 2, 2026.